Treatment Results of the Diabetic Macular Edema by Means of the PASCAL Laser System
Authors:
J. Němčanský 1,2; J. Studnička 3; S. Němčanská 1; D. Šalounová 4; D. Cholevík 1,2; P. Mašek 1,2
Authors‘ workplace:
Oční klinika Fakultní nemocnice, Ostrava, přednosta MUDr. Petr Mašek, CSc., FEBO
1; Ostravská univerzita v Ostravě, Lékařská fakulta, Katedra kraniofaciálních oborů, vedoucí katedry prof. MUDr. Pavel Komínek, Ph. D., MBA
2; Oční klinika Fakultní nemocnice, Hradec Králové, přednosta prof. MUDr. Pavel Rozsíval, CSc., FEBO
3; Vysoká škola báňská – Technická univerzita Ostrava, Ekonomická fakulta, Katedra matematických metod v ekonomice, vedoucí katedry doc. RNDr. Dana Šalounová, Ph. D.
4
Published in:
Čes. a slov. Oftal., 71, 2015, No. 5, p. 230-236
Category:
Original Article
Overview
Objective:
To evaluate functional, anatomical and clinical efficacy, and safety of the pattern scanning laser (PASCAL®) photocoagulation in patients with diabetic macular edema and absence of proliferative diabetic retinopathy.
Methods:
From 2008 to 2013 84 eyes of 58 patients (30 men, 28 women) were treated with pattern laser photocoagulation at the Ophthalmology Department at University Hospital Ostrava. Average age at the baseline visit was 65 years. The inclusion criteria included nonproliferative diabetic retinopathy (84 eyes), focal DME (14 eyes), diffuse exudative DME (70 eyes). All the eyes were „treatment naive“. The average duration of diabetes was 18 years, average baseline HbA1c value was 8,4%. Either focal laser photocoagulation or grid photocoagulation was performed with the PASCAL photocoagulator. Best corrected visual acuity (BCVA), central retinal thickness (CRT), fundus photography, biomicroscopy and complications were evaluated during the minimum 12months follow-up period. Statistical analysis using parametrical and nonparametrical tests with p less than 0,05 was done.
Results:
Mean baseline BCVA was 0,43 logMAR. Values 0,38, 0,37, 0,38 a 0,38 logMAR were observed in the follow-up intervals in the 4th, 6th, 12th and 18th month. In 4 eyes (5%) improvement of more than 3 lines was observed, in 26 eyes (31%) improvement from 0 to 3 lines was observed, in 52 eyes (62%) decrease from 0 to 3 lines was observed and in 2 eyes (2%) decrease of more than 3 lines was observed. Mean baseline CRT was 398 µm, values 370 µm, 362 µm, 349 µm and 338 µm were observed in the follow-up intervals in the 4th, 6th, 12th and 18th month. At the 12th month visit 76 eyes (90%) were stabilized, and in 8 eyes (10%) progression of the disease was observed. No complications were observed during the first 12 monhts follow up.
Conclusion:
Pattern scanning laser photocoagulation of DME lead to BCVA and clinical stabilization. In addition to this, it lead to decrease of the CRT. The efficacy was comparable to traditional laser systems with no apparent benefit to the traditional systems. The efficacy was inferior to modern intraocular anti-VEGF (vascular endothelial growth factor) drugs.
Key words:
diabetic macular edema, pattern scanning laser, short pulse duration
Sources
1. American Academy of Ophthalmology Retina/Vitreous Panel: Preffered Practice Pattern® Guidelines. Diabetic Retinopathy. [online]. San Francisco, CA: American Academy of Ophthalmology. 2014, [cit. 2015-03-03]. Dostupné z: <http://www.aao.org/ppp>
2. Berger, A., Sheidow, T., Cruess, A., F. et al.: Efficacy/safety of ranibizumab monotherapy or with laser versus laser monotherapy in DME. Can J Ophthalmol, 50; 2015, 3: 209–16.
3. Boguszaková, J., Doležalová, J., Gajdošíková, Z. et al.: Diabetická makulopatie. Čs Oftalmol, 50; 1994, Suppl: S12–8.
4. Bolz, M., Kriechbaum, K., Simader, C. et al.: In vivo retinal morphology after grid laser treatment in diabetic macular edema. Ophthalmology, 117; 2010, 3: 538–44.
5. Bresnick, G. H.: Diabetic macular edema. A review. Ophthalmology, 93; 1986, 7:989-97.
6. Comyn, O., Sivaprasad, S., Peto, T. et al.: A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). Am J Ophthalmol, 157; 2014, 5: 960–70.
7. Diabetic Retinopathy Clinical Research Network, Elman, M., J., Qin, H. et al.: Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology, 119; 2012, 11: 2312–8.
8. Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 103; 1985, 12: 1796–806.
9. Early Treatment Diabetic Retinopathy Study Research Group: Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology, 94; 1987, 7: 761–774.
10. Early Treatment Diabetic Retinopathy Study Research Group: Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report no. 3. Int Ophthalmol Clin. 27; 1987, 4: 54–264.
11. Ghanchi, F., Diabetic Retinopathy Guidelines Working Group: The Royal College of Ophthalmologists‘ clinical guidelines for diabetic retinopathy: a summary. Eye, 27; 2013, 2: 285–7.
12. Ishibashi, T., Li, X., Koh, A. et al.: The REVEAL Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Asian Patients with Diabetic Macular Edema. Ophthalmology, 122; 2015, 7: 1402–15.
13. Jain, A., Collen, J., Kaines, A. et al.: Short-duration focal pattern grid macular photocoagulation for diabetic macular edema: four-month outcomes. Retina, 30; 2010, 10: 1622–6.
14. Kalvodová, B., Sosna, T., Řehák, J. et al.: Doporučené postupy pro diagostiku a léčbu diabetické retinopatie. Čes a Slov Oftalmol, 68; 2012, 6: 236–41.
15. Kalvodová, B.: Současný stav diagnostiky a screeningu diabetické retinopatie a diabetického makulárního edému. Vnitř Lék, 59; 2013, 3: 182–6.
16. Lavinsky, D., Sramek, C., Wang, J. et al.: Subvisible retinal laser therapy: titration algorithm and tissue response. Retina, 34; 2014, 1: 87–97.
17. Luttrull, J., K., Much, D., C., Mainster, M., A.: Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic maculare oedema. Br J Ophthalmol, 89; 2005, 1: 74–80
18. McDonald, H., R., Schatz, H.: Grid photocoagulation for diffuse macular edema. Retina, 5; 1985, 2: 65–72.
19. Mitchell, P., Bandello, F., Schmidt-Erfurth, U. et al.: The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology, 118; 2011, 4: 615–25.
20. Muqit, M., M., Gray, J., C., Marcellino, G., R. et al.: Barely visible 10-millisecond pascal laser photocoagulation for diabetic macular edema: observations of clinical effect and burn localization. Am J Ophthalmol, 149; 2010, 6: 979–986.
21. Modi, D., Chiranand, P., Akduman, L.: Efficacy of patterned scan laser in treatment of macular edema and retinal neovascularization. Clin Ophthalmol, 2009, 3: 465–70.
22. Mylonas, G., Bolz, M., Kriechbaum, K. et al.: Retinal architecture recovery after grid photocoagulation in diabetic macular edema observed in vivo by spectral domain optical coherence tomography. Retina, 33; 2013, 4: 717–25.
23. Olk, R., J.: Modified grid argon (blue-green) laser photocoagulation for diffuse diabetic macular edema. Ophthalmology, 93; 1986, 7: 938–50.
24. Rajendram, R., Fraser-Bell, S., Kaines, A. et al: A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol, 130; 2012, 8: 972–9.
25. Řehák J., Chrapek O., Prachařová Z., Gbelcová M.: Naše zkušenosti v léčbě diabetické makulopatie. Čes a Slov Oftalmol, 60; 2004, 2: 112–7.
26. Sanghvi, C., McLauchlan, R., Delgado, C. et al.: Initial experience with the Pascal photocoagulator: a pilot study of 75 procedures. Br J Ophthalmol, 92; 2008, 8: 1061-4.
27. Sheth, S., Lanzetta, P., Veritti, D. et al.: Experience with the Pascal® photocoagulator: an analysis of over 1,200 laser procedures with regard to parameter refinement. Indian J Ophthalmol, 59; 2011, 2: 87–91.
28. Studnička, J., Lášticová, M., Sosna, T. et al.: Diabetický makulární edém z pohledu oftalmologa a diabetologa. Postgraduální medicína. 15; 2013, 4: 376–80.
29. The Diabetic Retinopathy Study Research Group: Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group. Am J Ophthalmol, 81; 1976, 4: 383–96.
30. The Diabetic Retinopathy Study Research Group.: Photocoagulation treatment of proliferative diabetic retinopathy. The second report of diabetic retinopathy study findings. Ophthalmology, 85; 1978, 1: 82–105.
31. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Fong D, S., Strauber S. F. et al.: Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol, 125; 2007, 4: 469–80.
Labels
OphthalmologyArticle was published in
Czech and Slovak Ophthalmology
2015 Issue 5
Most read in this issue
- Eye Myiasis – a Case Report
- Surgical Treatment of Diplopia in Patients with Endocrine Orbitopathy
- Solar Maculopathy after Watching the Partial Solar Eclipse
- Treating Diabetic Macular Edema by a Micropulse Laser – First Findings